MDR1 polymorphism influences the outcome of multiple myeloma patients.
The multidrug resistance gene (MDR1) has been reported to be an additional prognostic factor in acute myeloid leukaemia patients. This study evaluated the prognostic role of MDR1 in the outcome of 115 multiple myeloma patients treated with DAV (dexamethasone, doxorubicin [adryamicin] and vincristine) regimen followed by autologous transplantation. In particular, when investigating the C3435T polymorphism, a prognostic value of MDR1 genotypes for overall survival (OS) was observed. Our data suggested a longer OS for patients with C/T and T/T genotypes (log-rank test, P = 0.02) compared with patients with C/C genotype.
Buda
Gabriele
G
Department of Oncology, Transplants and Advanced Technologies, Section of Hematology, Pisa University, Pisa, Italy. ga.buda@libero.it
Maggini
Valentina
V
Galimberti
Sara
S
Martino
Alessandro
A
Giuliani
Nicola
N
Morabito
Fortunato
F
Genestreti
Giovenzio
G
Iacopino
Pasquale
P
Rizzoli
Vittorio
V
Barale
Roberto
R
Rossi
Anna M
AM
Petrini
Mario
M
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D019450:Genes, MDR; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D016019:Survival Analysis; D014750:Vincristine / Q000008:administration & dosage
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin